bluebird bio, Inc. (BLUE)
NASDAQ: BLUE · Real-Time Price · USD
4.080
-2.960 (-42.05%)
At close: Feb 21, 2025, 4:00 PM
3.990
-0.090 (-2.21%)
After-hours: Feb 21, 2025, 7:50 PM EST
bluebird bio Revenue
bluebird bio had revenue of $10.61M in the quarter ending September 30, 2024, a decrease of -14.36%. This brings the company's revenue in the last twelve months to $53.12M, up 144.50% year-over-year. In the year 2023, bluebird bio had annual revenue of $29.50M with 720.04% growth.
Revenue (ttm)
$53.12M
Revenue Growth
+144.50%
P/S Ratio
0.67
Revenue / Employee
$141,653
Employees
375
Market Cap
39.67M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
BLUE News
- 18 hours ago - ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of bluebird bio, Inc. - PRNewsWire
- 20 hours ago - Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker - CNBC
- 1 day ago - bluebird bio Stock Alert - Kehoe Law Firm, P.C. Investigating the Fairness and Adequacy of the Proposed Acquisition of bluebird bio by Investment Firms in Collaboration with Biotech Execs - Accesswire
- 1 day ago - Bluebird bio to be taken private by Carlyle and SK Capital amid cash crunch - Reuters
- 1 day ago - bluebird bio Announces Definitive Agreement to be Acquired by Carlyle and SK Capital - Business Wire
- 4 days ago - High-cost sickle cell gene therapies push insurers and Medicaid programs to find new payment models - CNBC
- 2 months ago - bluebird bio Presents Positive Long-Term Data On LYFGENIA™ (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and Exposition - Business Wire
- 2 months ago - Long-Term Follow-Up Data Continue to Support Beti-Cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels - Business Wire